التفاصيل البيبلوغرافية
| العنوان: |
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. |
| المؤلفون: |
Gan, Hui K., Parakh, Sagun, Lee, F. T., Tebbutt, Niall C., Ameratunga, Malaka, Lee, Sze Ting, O'Keefe, Graeme J., Gong, Sylvia J., Vanrenen, Christine, Caine, Jaren, Giovannetti, Mara, Murone, Carmel, Scott, Fiona E., Guo, Nancy, Burvenich, Ingrid J. G., Paine, Cameron, Macri, Mary J., Kotsuma, Masakatsu, Senaldi, Giorgio, Venhaus, Ralph |
| المصدر: |
Investigational New Drugs; Aug2022, Vol. 40 Issue 4, p747-755, 9p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, ADENOCARCINOMA, STOMACH tumors, PANCREATIC tumors, DISEASE progression, METASTASIS, MONOCLONAL antibodies, CELL receptors, HEAD & neck cancer, TREATMENT effectiveness, DIAGNOSTIC imaging, RANDOMIZED controlled trials, PRE-tests & post-tests, COMPARATIVE studies, CANCER patients, COLORECTAL cancer, POSITRON emission tomography, DOSE-effect relationship in pharmacology, DESCRIPTIVE statistics, TUMORS, STATISTICAL sampling, PATIENT safety, EVALUATION |
| مستخلص: |
Ephrin type-A 2 (EphA2) is a transmembrane receptor expressed in epithelial cancers. We report on a phase I dose escalation and biodistribution study of DS-8895a, an anti-EphA2 antibody, in patients with advanced EphA2 positive cancers. DS-8895a was administered at 1, 3, 10 or 20 mg/kg every 2 weeks to determine safety, pharmacokinetics and anti-tumor efficacy. All patients underwent 89Zr trace-labelled infusion of DS-8895a (89Zr-DS-8995a) positron emission tomography imaging to determine the biodistribution of DS-8895a, and correlate findings with EphA2 expression, receptor saturation and response. Nine patients were enrolled on study. Of patients enrolled, seven patients received at least one infusion of DS-8895a: four patients received 1 mg/kg dose (Cohort 1) and three patients received 3 mg/kg dose (Cohort 2). Median age was 67.0 years (range 52—81), majority male (71%), and median number of prior systemic therapies was three (range 0—8). The primary cancer diagnosis was colorectal cancer (two patients) and one patient each had gastric, head and neck, high-grade serous adenocarcinoma, lung, and pancreatic cancers. No dose-limiting toxicities or treatment-related adverse events reported. The best response for the patients in Cohort 1 was stable disease and in Cohort 2 was progressive disease. 89Zr-DS-8895a demonstrated no normal tissue uptake and specific low-grade uptake in most tumours. DS-8895a had limited therapeutic efficacy at doses evaluated and 89Zr-DS-8895a demonstrated low tumour uptake. The biodistribution data from this study were key in halting further development of DS-8895a, highlighting the importance of biodistribution studies in drug development. (Trial registration: ClinicalTrials.gov Identifier NCT02252211). [ABSTRACT FROM AUTHOR] |
|
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder